JPRN-UMIN000003433
Completed
Phase 2
The phase II study for evaluating the effectiveness and safety of allogeneic hematopoietic stem cell transplantation for adult acute myeloid leukemia with FLT3/ITD mutation. -JALSG AML209-FLT3-SCT Study (AML209-FLT3-SCT)- - Allogeneic hematopoietic stem cell transplantation for adult acute myeloid leukemia with FLT3/ITD mutation.
ConditionsAcute myeloid leukemia
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Acute myeloid leukemia
- Sponsor
- Japan adult leukemia study group
- Enrollment
- 60
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •(1\)Secondary AML (2\)The patients with the past history of hematopoietic disorder. (3\)The patients who received the induction therapy consisted of Gemtuzumab ozogamicin (Mylotarg). (4\)The patients who have been identified the cancer after the registration to the JALSG AML209\-GS study. (5\)The patients who have developed myocardial infarction or angina after the registration to the JALSG AML209\-GS study. (6\)The patients with cardiac dysfunction. (7\)The patients with active gastric ulcer. (8\)The patients with the uncontrollable ileus. (9\)The patients with the diabetes mellitus. (10\)The patients with active infection. (11\)The patients in whom the HBV\-reactivation have been observed. (12\)Psycological patients.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A study assessing the combination of TG4010 and nivolumab with standard treatment in patients with advanced non small cell lung cancer.Stage IIIB-IV non small cell lung cancer (NSCLC)MedDRA version: 20.0Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 100000015841Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2016-005115-41-HUTransgene S.A.39
Active, not recruiting
Phase 1
A study assessing the combination of TG4010 and nivolumab with standard treatment in patients with advanced non small cell lung cancer.Stage IIIB-IV non small cell lung cancer (NSCLC)MedDRA version: 20.0Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2016-005115-41-BETransgene S.A.44
Active, not recruiting
Phase 1
A study assessing the combination of TG4010 and nivolumab with standard treatment in patients with advanced non small cell lung cancer.Stage IIIB-IV non small cell lung cancer (NSCLC)MedDRA version: 20.0Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2016-005115-41-DKTransgene S.A.39
Active, not recruiting
Phase 1
Phase II Study for the Evaluation of the Efficacy of Gemcitabine plus Erlotinib in Rash-positive Patients with metastatic pancreatic cancer and good risk factorsmetastatic pancreatic carcinomaMedDRA version: 18.1Level: LLTClassification code 10033576Term: Pancreas carcinomaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2011-005471-17-DEKlinikum der Universität München-Großhadern150
Active, not recruiting
Not Applicable
A clinical study evaluating the efficacy of topical cromoglicate solution compared to placeboin the treatment of mastocytosismastocytosisMedDRA version: 15.0Level: PTClassification code 10012812Term: Diffuse cutaneous mastocytosisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 15.0Level: LLTClassification code 10056452Term: Indolent systemic mastocytosisSystem Organ Class: 10005329 - Blood and lymphatic system disordersTherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2011-006275-20-DEEO Pharma A/S